Steve Debenport / iStockphoto.com
Healthcare investment yields the best returns when focusing on its core aims and forging strong partnerships, James Flynn, managing partner of Deerfield, tells LSIPR.
Managing around $8 billion in funds, Deerfield is a big player in the healthcare investment field. The firm focuses on every area of healthcare (including healthcare services, medical devices, pharmaceuticals and biotech) at every stage of development, from funding academic research before it’s been spun out through to public markets. At any one point in time, Illinois-based Deerfield has approximately 300 investments.
While these are impressive statistics, this is not the only reason James Flynn was selected for LSIPR 50. His role in making Deerfield an “important agent of change in advancing healthcare” merited his inclusion in the list.
Flynn joined Deerfield in 2000, at a time when it was operating as a public equity trading firm. Since then, he’s been on a mission to make Deerfield important to human health by creating infrastructure and activities to fill in social gaps where the company sees them.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
LSIPR 50 2018, James Flynn, Deerfield, healthcare, diversity, cancer, genetics, therapeutic research, children's healthcare, investment